British journal of haematology
Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.
Filippo Bagnoli, Jacopo Calabrese De Feo, Francesca Ricci, Francesco Corrado, Daniele Mannina, Daoud Rahal, Arturo Bonometti, Marcello Rodari, Laura Giordano, Stefania Bramanti, Carmelo Carlo-Stella, Armando Santoro
Published: 202610.1111/bjh.70292
Abstract
The prognosis of peripheral T-cell non-Hodgkin lymphomas (PTCL) is dismal, particularly in the relapsed/refractory (r/r) setting, where 3-year overall survival (OS) is 20%-30%. No superior second-line therapy for PTCL has been universally established…
Preview only. Read the full abstract at the source